

## Steroid Hormones and Endocrine Disruptors: Recent Advances in Receptor-Mediated Actions

Dono Indarto\* and Masao Izawa

*Department of Biosignaling, Tottori University Faculty of Medicine, Yonago 683-0826 Japan*

It has been accepted that receptor-mediated action of steroid hormones depends on both the receptor and the hormonal level. The mechanism of transcription by steroid receptors is mediated by cofactors, which function as co-activators or co-repressors, while their non-genomic actions depend on receptors localized to the cell membrane. Recently, a number of environmental chemicals, which are now termed as endocrine disruptors, have been identified, and their unwanted effects on our lives have become serious problems all over the world. Their adverse effects on endocrine systems in animals, mostly estrogenic or anti-estrogenic, have resulted in reproductive malfunction and developmental disorders. Although aryl hydrocarbons exhibit estrogenic or anti-estrogenic activity through specific interaction with aryl hydrocarbon receptors, other chemicals seem to interact directly with estrogen receptors,  $\alpha$  and  $\beta$  forms. In this paper, we surveyed the most recent understanding of endocrine disruptors from the viewpoint of steroid receptor systems. We suggest two potential mechanisms of action for endocrine disruptors. Endocrine disruptors i) directly associate with steroid receptor systems and/or ii) associate with the growth factor or the neurotransmitter receptor systems, and then upregulate the mitogen-activated protein kinase signaling cascades, leading to the ligand-independent activation of steroid receptor systems. Using these steroid receptor-dependent mechanisms, it appears that endocrine disruptors disorder our endocrine systems. We have proposed future suggestions to further understand endocrine disruptors from the viewpoint of steroid receptor systems.

**Key words:** endocrine disruptors; receptor-mediated actions; steroid hormones

Since the cloning of human glucocorticoid receptor (Hollenberg et al., 1985), a number of nuclear receptors including steroid receptors have been identified (Mangelsdorf et al., 1995; Pfaff et al., 1997), and are now understood as transcription factors included in a nuclear receptor superfamily (Freedman, 1999). Recently, estrogen receptors (ERs) have been shown to localize to the cell membrane, and their role in non-genomic actions have been demonstrated as well (Chen et al., 1999; Goetz et al., 1999).

A number of environmental chemicals have been identified as endocrine disruptors, and their unwanted effects on our lives have become serious problems all over the world. At present, their adverse effects on endocrine systems in animals, mostly estrogenic or anti-estrogenic, have resulted in reproductive malfunction and developmental disorders (Keith, 1997). Among endocrine disruptors identified so far, aryl hydrocarbons, dioxins, exhibit estrogenic or anti-estrogenic activity through specific inter-

---

Abbreviations: AhR, aryl hydrocarbon receptor; AR, androgen receptor; ARE, androgen responsive element; DES, diethylstilbeterol; EGF, epidermal growth factor; ER, estrogen receptor; ERE, estrogen responsive element; IGF, insulin-like growth factor; LBD, ligand binding domain; MAP mitogen-activated protein; PR, progesterone receptor; PRE, progestin responsive element; PHA, polycyclic aromatic hydrocarbon

\* Present address: Sebelas Maret University, Surakarta 57126, Indonesia. Short-term student exchange promotion program, Tottori University, supported by AIEJ 2000.


action with aryl hydrocarbon receptors (AhRs) (Osteen et al., 1997), while most other chemicals seem to interact directly with the ER system.

In this paper, we give a brief overview of the recent understanding of the receptor-mediated actions of steroid hormones, and discuss the receptor-mediated actions of endocrine disruptors.

### Recent advances in the mechanism of action of steroids

Nuclear receptors including steroid receptors have been understood as transcription factors, which mediate extracellular signals to the nucleus. A carboxy-terminus region of steroid receptors, the ligand binding domain (LBD), specifically interacts with cognate ligands, while the AF-2 domain recruits cofactors (Freedman, 1999; also see Fig. 1). Once associated with estrogens, ER is activated and recruits co-activators such as those from the SRC-1 family and TIF2/GRIP1/NCoA2, to interact with the estro-

gen responsive element (ERE) in responsive genes (McKenna and O'Malley, 2000; Freedman, 1999). When bound by an estrogen antagonist, ER recruits N-CoR and SMRT, co-repressors, and inhibits the transcription of estrogen responsive genes (McKenna and O'Malley, 2000). The concept of ER-dependent genomic actions has been accepted for other steroid receptor systems. Recently, growth factors, neurotransmitters and cyclins have been demonstrated to crosstalk with steroid receptor systems. Epidermal growth factor (EGF), insulin-like growth factor (IGF) (Kato et al., 1995; Bunone et al., 1996) and dopamine (Mani et al., 1994) could activate ER $\alpha$  via the mitogen-activated protein (MAP) kinase pathway in a ligand-independent manner. Cyclins directly interact with the unliganded ER $\alpha$  (Zwijsen et al., 1997). Progesterone receptor (PR) is also activated by dopamine through cAMP-dependent phosphorylation, and associates with SRC-1e, a co-activator specific for PR, to interact with the progestin responsive element (PRE) (Bai et al., 1997; Brossens et al., 1999). On the other hand,



**Fig. 1.** Mechanism of action of steroid hormones and endocrine disruptors. **A:** Genomic action. Steroid hormones and endocrine disruptors directly interact with intracellular steroid receptors. This leads to the recruitment of cofactors for specific interaction with hormone responsive elements (HREs) in hormone responsive genes. On the other hand, endocrine disruptors interact with receptors for growth factors or neurotransmitters to up-regulate mitogen-activated protein (MAP) kinase signaling. This leads to the ligand-independent activation of steroid receptors for the association with cofactors as described above. **B:** Non-genomic action. Steroid hormones and endocrine disruptors associate with steroid receptors localized to the cell membrane. This leads to the intracellular signaling pathways.

androgen receptor (AR) is activated by EGF, IGF and keratinocyte growth factor (KGF) through MAP kinase cascades, and binds to AP-1 and Ets, a co-activator specific for AR, to interact with the androgen responsive element (ARE) (Klocker et al., 1999; Culig et al., 1994).

Along with the ligand-dependent and the ligand-independent genomic actions, non-genomic actions through the plasma membrane receptor have recently been demonstrated to play important roles in hormone responsive cells (Chen et al., 1999; Goetz et al., 1999). In summary, the steroid receptor system is not only a ligand-induced transcriptional enhancer, but also a mediator of common intracellular signaling pathways in multiple cell types.

### **Endocrine disruptors and the mechanism of action**

Adverse effects of pharmaceuticals, industrial waste and environmental pollutants (now all acknowledged as endocrine disruptors) on our lives have become a serious problem in the world. They disorder the endocrine system in animals directly or indirectly. It is obvious that they exert their effects in a receptor-dependent manner (Brouwer et al., 1998; Chia, 2000; Fenner-Crisp, 2000).

Endocrine disruptors, which seemed to be closely related to ER systems, could be classified into three groups: estrogen mimics, anti-estrogens and anti-androgens (Sonnenschein and Soto, 1998; Gray et al., 1999a). An initial target for these compounds is ER (Nishikawa et al., 1999). Diethylstilbesterol (DES), a synthetic estrogen, behaves as an estrogen agonist (Hunter et al, 1999), and exposure to DES during the fetal period induces urogenital abnormalities in males (Kuiper et al., 1998; Spearow et al., 1999), oligospermia (Krishnan et al., 1993; Vom Saal et al., 1997), the increased incidence of undescended testis (Kuiper et al., 1998; Spearow et al., 1999) and hypertrophy of the prostate (Newbold, 1995). Polycyclic aromatic hydrocarbons (PAHs) have an anti-estrogenic activity through AhR (Brouwer et al., 1998; Safe et al., 1998; Loaiza-Perez et al.,

1999), and decrease the estrogen level in the blood (Kohn et al., 1993; Alvarez et al., 2000), the ER level in the uterus (De Vito et al., 1992; Alvarez et al., 2000) and the number of matured follicles associated with the upregulation of the follicle-stimulating hormone (Alvarez et al., 2000). Endocrine disruptors, which seemed to be closely related to AR systems are Flutamide, vinclozolin, p,p'-DDE and procymidone, anti-androgens, which disorder prostate maturation (Gray et al., 1999b), and induce undescended testis (Gray et al., 1999b), hypospadias (Gray et al., 1999b; Ostby et al., 1999) and permanent nipples (Gray et al., 1999b; Ostby et al., 1999) during sex differentiation. In adult animals, anti-androgens increase the serum levels of androgens, luteinizing hormone and estrogens (Ladics et al, 1998; Monosson et al., 1999), and induces spontaneous abortions, stillbirths, reproductive malfunction, neuroendocrine alteration, and disorder of immune systems (Goldman, 1997; Palanza et al, 1999; Alvarez et al., 2000).

As demonstrated above, disorder of steroid receptor-mediated signaling systems by endocrine disruptors leads to abnormal conditions in animal physiology. It is important to note that some endocrine disruptors exhibit potential activities: (i) to interact directly with endogenous steroids, (ii) to inhibit steroid receptor binding, non-competitively or (iii) to destroy receptor molecules or endogenous steroids (Sonnenschein and Soto, 1998; Soto et al., 1998).

### **Conclusion**

Ligand-dependent and -independent signaling pathways by steroid receptors seem to provide insights into the understanding of the molecular basis of endocrine disruptors as summarized in Fig. 1. We also summarized representative endocrine disruptors identified so far in Table 1. Although a number of endocrine disruptors in our daily lives have been identified, little is known about their molecular basis. It becomes an urgent subject to further understand the molecular basis of the diverse actions of endocrine

**Table 1. Representative endocrine disruptors**

Compound	Use	Receptor	Reference
DES	Medicine	ER $\alpha$ , ER $\beta$	23, 30
Bisphenol A		ER $\alpha$ , ER $\beta$	23, 37
Nonylphenol		ER $\alpha$ , ER $\beta$	23, 37
PAHs:HCB, HCH	Pesticide	AhR	25, 36
o,p'-DDT		ER $\alpha$ , ER $\beta$	23
p,p'-DDT		ER $\alpha$ , ER $\beta$	23
Methoxychlor		ER $\alpha$ , ER $\beta$	23
Endosulfan		ER $\alpha$ , ER $\beta$	23
Chlordecone		ER $\alpha$ , ER $\beta$	23
p,p'-DDE		AR	14, 15, 32
Linuron		AR	14, 15, 32
Vinclozolin		AR	14, 15, 32
Procymidone		AR	14, 15, 32
PCBs		Industrial waste	ER $\alpha$ , ER $\beta$
Bisphenol A	ER $\alpha$ , ER $\beta$		23, 37
4 Tert-octyphenol	ER $\alpha$ , ER $\beta$		23, 37
4-Octyphenol	ER $\alpha$ , ER $\beta$		23, 37
TCDD	AhR		36

AhR, aryl hydrocarbon receptor; AR, androgen receptor; DES, diethylstilbesterol; ER, estrogen receptor; HCB, hexachlorobenzene; HCH, hexachlorohexane; op'/pp'-DDT, dichlorodiphenyltrichloroethane; PAH, polycyclic aromatic hydrocarbon; PCB, polychlorinated hydroxybiphenyl; p,p'-DDE, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.

disruptors. Understanding endocrine disruptors from the viewpoint of steroid receptor-mediated signaling may allow us to overcome these global problems. In addition, it is obviously important to keep up international cooperation.

*Acknowledgments:* D. I. thanks Professor Kenzo Takeshita, former Dean of Tottori University Faculty of Medicine, for arranging the opportunity to visit Tottori University. We also thank Professor Takeshi Sairenji, Department of Biosignaling, Tottori University Faculty of Medicine, for his encouragement.

## References

- 1 Alvarez L, Randi A, Alvarez P, Piroli G, Chamson-Reig A, Lux-Lantos V, et al. Reproductive effects of hexachlorobenzene in female rats. *J Appl Toxicol* 2000;20:81–87.
- 2 Bai W, Rowan BG, Allgood VE, O'Malley BW, Weigel NL. Differential phosphorylation of chicken progesterone receptor in hormone dependent and ligand-independent activation. *J Biol Chem* 1997;272:10457–10463.
- 3 Brossens JJ, Hayashi N, White JO. Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. *Endocrinology* 1999;140:4809–4820.
- 4 Brouwers A, Morse DC, Lans MC, Schuur AG, Murk AJ, Klasson-Wehler E, et al. Interactions of persistent environmental organohalogenes with the thyroid hormone system: mechanism and possible consequences for animal and human health. *Toxicol Ind Health* 1998;14:59–84.
- 5 Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *EMBO J* 1996;15:2174–2183.

- 6 Chia SE. Endocrine disruptors and male reproductive function. *Int J Androl* 2000;2:45–46.
- 7 Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J Clin Invest* 1999;103:401–406.
- 8 Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. *Cancer Res* 1994;54:5474–5478.
- 9 DeVito MJ, Thomas T, Martin T, Umbreit H, Gallo MA. Antiestrogenic action of 2,3,7,8-tetrachlorodibenzo-p-dioxin: tissue-specific regulation of estrogen receptor in CD-1 mice. *Toxicol Appl Pharmacol* 1992;3:284–292.
- 10 Fenner-Crisp PA. Endocrine modulators: risk characterization and assessment. *Toxicol Pathol* 2000;28:438–440.
- 11 Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. *Cell* 1999;97:5–8.
- 12 Goetz RM, Thatte HS, Prabhaker P, Cho MR, Michel T, Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. *Proc Natl Acad Sci USA* 1000;96:2788–2793.
- 13 Goldman LR. New approaches for assessing the etiology and risks of developmental abnormalities from chemical exposure. *Reprod Toxicol* 1997;11:443–451.
- 14 Gray LE Jr, Ostby J, Monosson E, Kelce WR. Environmental antiandrogens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rat. *Toxicol Ind Health* 1999a;15:48–64.
- 15 Gray LE Jr, Wolf C, Lambricht C, Mann P, Price M, Cooper RL, et al. Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolate, p,p'-DDE, and ketokonazole) and toxic substances (dibutyl- and diethylphthalate, PCB 169, and ethane dimethane sulphate) during sexual differentiation produce diverse profiles of reproductive malformation in the male rat. *Toxicol Ind Health* 1999b;15:94–118.
- 16 Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro AE, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. *Nature* 1985;318:635–641.
- 17 Hunter DS, Hodges LC, Vonier PM, Fuchs-Young R, Gottardis MM, Walker CL. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. *Cancer Res* 1999;59:3090–3099.
- 18 Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 1995;270: 1491–1494.
- 19 Keith LH. *Environmental endocrine disruptors. A handbook of property data.* New York: John Wiley and Sons; 1997.
- 20 Klocker H, Culig Z, Eder IE, Nessler Menardi C, Hobisch A, Putz T, et al. Mechanism of androgen receptor activation and possible implication for chemoprevention trials. *Eur Urol* 1999;35:413–419.
- 21 Kohn MC, Lucier GM, Clark GC, Sewall CA. A mechanism model of effects of dioxin on gene expression in the rat liver. *Toxicol Appl Pharmacol* 1993;120:138–154.
- 22 Krishnan AV, Stathis P, Permuth SP, Tokes L, Feldman D, Bisphenol A. An estrogenic substance is released from polycarbonate flasks during autoclaving. *Endocrinology* 1993;132:2279–2286.
- 23 Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 1998;139: 4252–4263.
- 24 Ladics GS, Smith C, Nicastro SC, Loveless SE, Cook JC, O'Connor JC. Evaluation of the primary humoral immune response following exposure of male rats to 17beta-estradiol or flutamide for 15 days. *Toxicol Sci* 1998;46:75–82.
- 25 Loaiza-Perez AI, Seisdedos MT, Kleiman de Pisarev DL, Sancovich HA, Randi AS, Ferramola de Sancovich AM, et al. Hexachlorobenzene, a dioxin-type compound, increases malic enzyme gene transcription through a mechanism involving the thyroid hormone response element. *Endocrinology* 1999;140:4142–4151.
- 26 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. *Cell* 1995;83:835–839.
- 27 Mani SK, Allen JM, Clark JH, Blaustein JD, O'Malley BW. Convergent pathways for steroid hormone and neurotransmitter-induced rat sexual behavior. *Science* 1994;265:1246–1249.
- 28 McKenna NJ, O'Malley BW. An issue of tissues: divining the spilt personalities of selective estrogen receptor modulators. *Nature Med* 2000;6: 960–962.
- 29 Monosson E, Kelce WR, Lambricht C, Ostby J, Gray LE Jr. Peripubertal exposure to the antiandrogenic fungicide, vinclozolin, delays puberty, inhibits the development of androgen-dependent tissues, and alters androgen receptor function in the male rat. *Toxicol Ind Health* 1999;15: 65–79.
- 30 Newbold R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: im-

- plications for other environmental estrogens. *Environ Health Perspect* 1995;103:83–87.
- 31 Nishikawa J, Saito K, Goto J, Dakeyama F, Matsuo M, Nishihara T. New screening methods for chemical with hormonal activities using interaction of nuclear hormone receptor with coactivator. *Toxicol Appl Pharmacol* 1999;154:76–83.
- 32 Ostby J, Kelce WR, Lambright C, Wolf CJ, Mann P, Gray LE Jr. The fungicide procymidone alters sexual differentiation in the male rat by acting as an androgen-receptor antagonist in vivo and in vitro. *Toxicol Ind Health* 1999;15:80–93.
- 33 Osteen KG, Sierra-Rivera E. Does disruption of immune and endocrine systems by environmental toxins contribute to development of endometriosis? *Semin Reprod Endocrinol* 1997;15:301–308.
- 34 Palanza P, Morellini F, Parmigiani S, Vom Saal FS. Prenatal exposure to endocrine disrupting chemicals: effects on behavioral development. *Neurosci Biobehav Rev* 1999;23:1011–1027.
- 35 Pfaff DW. Hormones, genes, and behaviour. *Proc Natl Acad Sci USA* 1997;94:14213–14216.
- 36 Safe S, Wang F, Porter W, Duan R, Mcdougal A. Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanism. *Toxicol Lett* 1998;102:343–347.
- 37 Sonnenschein C, Soto AM. An updated review of environmental estrogen and androgen mimics and antagonists. *J Steroid Biochem Mol Biol* 1998; 65:143–150.
- 38 Soto AM, Michaelson CL, Prechtl NV, Weill BC, Sonnenschein C, Olea-Serrano F, et al. Assay to measure estrogen and androgen agonists and antagonists. *Adv Exp Med Biol* 1998;444:9–23.
- 39 Spearow JL, Doemeny P, Sera R, Leffler R, Barkley M. Genetic variation in susceptibility to endocrine disruption by estrogen in mice. *Science* 1999;285:1259–1261.
- 40 Vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. *Proc Natl Acad Sci USA* 1997;94:2056–2061.
- 41 Zwijsen RM, Wientjens E, Klomp maker R, van der Sman J, Bernarids R, Michalides RJAM. CDK-independent activation of estrogen receptor by cyclin D1. *Cell* 1997;88:405–415.

*Received December 27, 2000; accepted January 12, 2001*

*Correspondence:* Masao Izawa, PhD  
Department of Biosignaling  
Tottori University Faculty of Medicine  
86 Nishi-machi, Yonago 683-8503 JAPAN  
Tel and Fax: +81-859-34-8042  
E-mail: imizawa@grape.med.tottori-u.ac.jp